OTC · CHNXF
ChitogenX Inc.
$0.01$0.00 (0.0%)
ChitogenX Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
Loading market information…
OTC · RGRX · USD
Stock price, earnings
Quote as of Oct 28, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
RegeneRx Biopharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.33% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow RegeneRx Biopharmaceuticals, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
RegeneRx Biopharmaceuticals, Inc. is a biotechnology firm dedicated to the advancement of therapeutic peptides, with a primary emphasis on thymosin beta 4, engineered for the protection, repair, and regeneration of tissues and organs. The company's development pipeline includes RGN-259, a preservative-free ophthalmic solution designed to restore corneal tissues following injury, disease, or other pathologies; RGN-352, an injectable formulation under investigation for its potential in treating cardiovascular ailments, central and peripheral nervous system disorders, and various other medical conditions; and RGN-137, a topical gel aimed at accelerating the healing of skin wounds and minimizing scar tissue. Strategic alliances have been forged with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. Incorporated in 1982, the company initially operated as Alpha 1 Biomedicals, Inc., adopting the name RegeneRx Biopharmaceuticals, Inc. in 2000. Its operations are headquartered in Rockville, Maryland.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:45 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.01$0.00 (0.0%)
ChitogenX Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Actavia Life Sciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 87.5% below the high.
$0.00$0.00 (0.0%)
Forza Innovations Inc.: Healthcare · Medical - Devices.
$0.00$0.00 (0.0%)
BioSyntech, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.01-$0.00 (-0.89%)
Qrons Inc.’s quoted price sits in the lower half of its reported 52-week range, 93.58% below the high.
$0.00$0.00 (0.0%)
ViaDerma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.75% below the high.
$0.00$0.00 (0.0%)
Nascent Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.85% below the high.
$0.00$0.00 (0.0%)
Quantum Medical Transport, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
